Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 (MAR) and the Delegated EU Regulation 2016/1052 / Share Repurchase

QIAGEN reports results for second quarter and first half of 2017

DiaSorin and QIAGEN sign collaboration to expand liaison test menu through adoption of select QIAGEN assays

French health-system approves reimbursement of QIAGEN's QuantiFERON latent TB test 

QIAGEN's QuantiFERON®-TB Gold Plus gains U.S. FDA approval

Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

QIAGEN expands biomarker content portfolio to support greater use of molecular diagnostics for immuno-oncology therapies

QIAGEN reports results for first quarter 2017

QIAGEN partners with Maccura to localize and commercialize GeneReader NGS System in China

New research suggests potential for additional clinical utility of QIAGEN’s QuantiFERON-TB Gold Plus